Drug Type Small molecule drug |
Synonyms (3S,4S,5R)-1,3,4,5,6-pentahydroxyhexan-2-one, D-lyxo-hex-2-ulose, D-lyxo-hexulose + [4] |
Target- |
Action- |
Mechanism Iron chelating agents |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC6H12O6 |
InChIKeyBJHIKXHVCXFQLS-PQLUHFTBSA-N |
CAS Registry87-81-0 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | D-tagatose | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Prader-Willi Syndrome | Phase 3 | United States | 06 Aug 2020 | |
| Diabetes Mellitus, Type 2 | Phase 3 | United States | - | 01 Apr 2007 |
| Diabetes Mellitus, Type 2 | Phase 3 | India | - | 01 Apr 2007 |
| Hyperlipoproteinemia Type I | Phase 3 | - | - |
Phase 3 | 494 | Sugar Substitute Splenda (Sugar Substitute Splenda) | kcfdbixpty(nhkeirmwpj) = eahbfxjfje ejsjmzrrwg (hgkkmonpqq, 0.07) View more | - | 19 Nov 2014 | ||
(Tagatose) | kcfdbixpty(nhkeirmwpj) = njcyagryuv ejsjmzrrwg (hgkkmonpqq, 0.07) View more | ||||||
Phase 2 | 161 | (2.5 Active) | zdktzzuuik = qlpyznqnse aqfnkfzxhp (lpjcbatlbu, rjkycuxdjq - skjvvinejs) View more | - | 06 Nov 2014 | ||
(5.0 Mid Dose) | zdktzzuuik = uecvdmldap aqfnkfzxhp (lpjcbatlbu, rdwhqezwyz - ojoqiqtjxm) View more |





